The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.
about
Targeted therapies in sarcomas: challenging the challengeProtection from rapamycin-induced apoptosis by insulin-like growth factor-I is partially dependent on protein kinase C signalingSequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic LandscapesChildren's Oncology Group's 2013 blueprint for research: bone tumorsPotential approaches to the treatment of Ewing's sarcomaMetformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drugCombinational Therapy Enhances the Effects of Anti-IGF-1R mAb Figitumumab to Target Small Cell Lung CancerVorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK PathwaysReceptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease.Dual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategyDoes insulin-like growth factor 1 receptor (IGF-1R) targeting provide new treatment options for chordomas? A retrospective clinical and immunohistochemical study.Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.Northwestern profiling of potential translation-regulatory proteins in human breast epithelial cells and malignant breast tissues: evidence for pathological activation of the IGF1R IRES.Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma.Human monoclonal antibody fragments binding to insulin-like growth factors I and II with picomolar affinity.Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma.Can we unlock the potential of IGF-1R inhibition in cancer therapy?PTEN deficiency mediates a reciprocal response to IGFI and mTOR inhibition.Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing programThe combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trialInitial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing programTargeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and ExpectationsEmerging therapy for adrenocortical carcinoma.Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program.Targeted therapies for advanced Ewing sarcoma family of tumors.Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma.Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507.Treatment of Bone TumorsTargeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls.Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group.Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytomaPotent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2.PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcomaNew drugs and combinations for the treatment of soft-tissue sarcoma: a review.The Current and Future Therapies for Human Osteosarcoma.Recent advances in the molecular pathogenesis of Ewing's sarcoma.Ewing tumors that do not overexpress BMI-1 are a distinct molecular subclass with variant biology: a report from the Children's Oncology Group.Insulin-like growth factor: current concepts and new developments in cancer therapy.
P2860
Q21285014-52111514-4302-4B0E-8A39-2AC93BA5E3F8Q24300773-9F5EC25C-D7DB-4A8E-9BC0-E5D248C2AEECQ26801785-686E7FD4-511D-43D5-AFF9-092D72BA0159Q27027664-DEF5BAD5-4E16-4570-B590-048E322251FEQ28072744-2EA0DEC0-9B0D-4A63-9894-3C1C6025781AQ28538155-A37F146A-9EE7-4BAF-9A63-8602C21253ACQ28547364-968813DC-94E6-42E1-BC0E-CCE8FF9FEAC1Q28550980-A4913E52-F761-4485-87AF-420DB1C76C9DQ30315828-1F5CD6F7-BF95-4CD7-B632-661467BC54CBQ30540343-CF879F42-BEAB-419C-A30A-4B6954CDF701Q33274394-6ED38261-FEDB-41D7-89EB-3B27187F183CQ33396217-B16CBD56-2DD5-4003-9C21-DA8B4FEFB230Q33400495-1D5C6F11-AACA-4501-AD81-190CBFED8EF3Q33843662-1612F094-21A1-4250-9B32-AC77FF34116BQ33861173-7A7E7549-35C3-4A58-90F1-6D82E6E87CADQ33959016-0EF873A4-3E71-4E14-80F5-EBD0ED44233CQ34110523-F901B3E5-5748-4FD6-A310-BA9E73A4D91BQ34336988-3B633941-58DE-4CE1-B501-C00939CA1349Q34518277-EA834F82-229D-4284-AFA0-A8BB388527C7Q34592429-3524A165-9111-43C9-968C-10FEC4B3A767Q34984126-72521B3A-8F45-4EFF-A91A-F641C9E826D6Q35005309-C0066AA5-7A01-4802-861A-ED6D9BFF072FQ35013284-092A2F7E-5D38-4E17-B116-B8362B61956DQ35018399-A4F3D2D1-6731-4AAC-8BAD-257150BE9173Q35112340-C37D06CA-74C9-413D-90CC-5914A89A0372Q35194644-1D953F03-6714-48A2-98DC-790EC4D40A53Q35589492-1CACFAC6-CBF6-492D-8AAF-F1283875F23AQ35609719-92C9CE22-8137-48CD-9B81-9F7DE5A4BE20Q35627019-7AE7583B-8748-4230-90B2-8427B4E2FDFDQ35740708-3820175E-6916-43FE-8CD6-C8FA1E68E271Q35810171-BB0FB53C-FDDA-45E2-ABF8-FBE9510D9872Q35850208-902580C1-9670-4325-89B7-C77259A8E8FBQ36033783-59E0A832-E6D8-4683-A5B4-58F6A8590785Q36170917-CC22A3E2-BD87-4853-A23D-F60AA5BD5D4AQ36204986-728993E6-E264-40A1-9669-32467C1B0EBAQ36444369-A8F92BBB-5806-4333-9EC1-B1BDE0EE92FDQ36514299-BB090EF7-ABC6-4CCB-8F19-E589252092CAQ36562720-13DE7EA6-468F-4660-B5D1-F1FC451BD6FAQ37012862-B1C7231E-3324-42BC-8718-A7F74A7F06DAQ37047067-C39A9F66-0CFF-44B9-A254-86BA6DDF36FE
P2860
The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
The insulin-like growth factor ...... n models of childhood sarcoma.
@ast
The insulin-like growth factor ...... n models of childhood sarcoma.
@en
The insulin-like growth factor ...... n models of childhood sarcoma.
@nl
type
label
The insulin-like growth factor ...... n models of childhood sarcoma.
@ast
The insulin-like growth factor ...... n models of childhood sarcoma.
@en
The insulin-like growth factor ...... n models of childhood sarcoma.
@nl
prefLabel
The insulin-like growth factor ...... n models of childhood sarcoma.
@ast
The insulin-like growth factor ...... n models of childhood sarcoma.
@en
The insulin-like growth factor ...... n models of childhood sarcoma.
@nl
P2093
P2860
P1433
P1476
The insulin-like growth factor ...... n models of childhood sarcoma.
@en
P2093
Catherine Billups
Christopher L Morton
Larisa V Debelenko
Lorina Dudkin
Peter J Houghton
Raushan T Kurmasheva
P2860
P304
P356
10.1158/0008-5472.CAN-09-1693
P407
P577
2009-09-29T00:00:00Z